Ser166
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.0.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser166  -  RIPK1 (human)

Site Information
LAsFkMWskLNNEEH   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 27116401

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 1 ) , immunoprecipitation ( 4 ) , mass spectrometry ( 9 ) , mass spectrometry (in vitro) ( 10 ) , mutation of modification site ( 2 ) , phospho-antibody ( 1 , 2 , 3 , 4 , 5 , 6 , 8 ) , western blotting ( 2 , 3 , 4 , 5 , 6 , 8 )
Disease tissue studied:
breast cancer ( 9 ) , breast ductal carcinoma ( 9 ) , colorectal cancer ( 4 , 6 ) , colorectal carcinoma ( 4 , 6 ) , lymphoma ( 6 ) , oropharyngeal cancer ( 3 ) , squamous cell carcinoma of the oropharynx ( 3 ) , fibrosarcoma of soft tissue ( 5 , 6 )
Relevant cell line - cell type - tissue:
3T3 (fibroblast) ( 6 ) , brain ( 8 ) , breast ( 9 ) , CNE-2 (squamous) ( 3 ) , HCT116 (intestinal) ( 4 ) , HeLa (cervical) ( 2 , 4 ) , HT-29 (intestinal) ( 6 ) , L929 (fibroblast) ( 5 , 6 ) , MEF (fibroblast) ( 4 , 5 ) , mononuclear-blood ( 1 ) , U-937 (myeloid) ( 6 )

Upstream Regulation
Regulatory protein:
FILIP1 (human) ( 4 ) , MIB2 (human) ( 4 ) , ULK1 (human) ( 5 )
Putative in vivo kinases:
RIPK1 (human) ( 2 , 3 , 4 , 5 )
Kinases, in vitro:
RIPK1 (human) ( 10 )
Treatments:
BV6 ( 4 ) , cycloheximide ( 4 ) , MRT68921 ( 5 ) , Necrostatin-1 ( 2 , 4 ) , phenhydan ( 6 ) , Q-VD-OPh ( 5 ) , SAR443060 ( 1 ) , SBI-0206965 ( 5 ) , SM-164 ( 1 ) , smac ( 2 ) , TNF ( 1 , 2 , 4 , 5 , 6 ) , Z-VAD-FMK ( 1 , 2 , 4 , 5 , 6 )

Downstream Regulation
Effects of modification on RIPK1:
enzymatic activity, inhibited ( 3 ) , molecular association, regulation ( 4 ) , phosphorylation ( 2 )
Effects of modification on biological processes:
apoptosis, induced ( 4 )
Induce interaction with:
CASP8 (human) ( 4 ) , FADD (human) ( 4 )

Disease / Diagnostics Relevance
Relevant diseases:
multiple sclerosis ( 8 )

References 

1

Vissers MFJM, et al. (2022) Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients. Clin Transl Sci
35649245   Curated Info

2

Chen X, et al. (2022) Mosaic composition of RIP1-RIP3 signalling hub and its role in regulating cell death. Nat Cell Biol
35256774   Curated Info

3

You B, et al. (2021) AMPK-mTOR-mediated activation of autophagy promotes formation of dormant polyploid giant cancer cells. Cancer Res
34965934   Curated Info

4

Nakabayashi O, et al. (2021) MIND bomb 2 prevents RIPK1 kinase activity-dependent and -independent apoptosis through ubiquitylation of cFLIP. Commun Biol 4, 80
33469115   Curated Info

5

Wu W, et al. (2020) The Autophagy-Initiating Kinase ULK1 Controls RIPK1-Mediated Cell Death. Cell Rep 31, 107547
32320653   Curated Info

6

Moerke C, et al. (2018) The anticonvulsive Phenhydan suppresses extrinsic cell death. Cell Death Differ
30442947   Curated Info

7

Feltham R, et al. (2018) Mind Bomb Regulates Cell Death during TNF Signaling by Suppressing RIPK1's Cytotoxic Potential. Cell Rep
29642005   Curated Info

8

Ofengeim D, et al. (2015) Activation of necroptosis in multiple sclerosis. Cell Rep 10, 1836-49
25801023   Curated Info

9

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

10

Degterev A, et al. (2008) Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 4, 313-21
18408713   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.